Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：2
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Hoylman, Emily
    Brown, Anna
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Pianko, Matthew
    Ye, Jing Christine
    Campagnaro, Erica
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 691 - 698
  • [42] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [43] Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Takafumi Ide
    Mayu Osawa
    Kinjal Sanghavi
    Heather E. Vezina
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 129 - 140
  • [44] Daratumumab-resistant multiple myeloma with extramedullary disease successfully treated with combination elotuzumab, pomalidomide and dexamethasone: A case report
    Sakashita, Masataka
    Sahara, Naohi
    Aoki, Jun
    Matsunaga, Takashi
    Kobayashi, Seiichiro
    Kitahara, Shinsuke
    Fujii, Tomoki
    Ohno, Nobuhiro
    ONCOLOGY LETTERS, 2024, 27 (06)
  • [45] Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution
    Abdallah, Al-Ola
    McGuirk, Joseph P.
    Shune, Leyla
    Dunavin, Neil
    Mahmoudjafari, Zahra
    Hochard, Erica
    Ganguly, Siddhartha
    BLOOD, 2017, 130
  • [46] Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience
    Abdallah, Al-Ola
    Dunavin, Neil
    McClune, Brian
    Shune, Leyla
    Dias, Ajoy L.
    Mahmoudjafari, Zahra
    Hochard, Erica
    McGuirk, Joseph P.
    Ganguly, Siddhartha
    BLOOD, 2018, 132
  • [47] A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma
    Van Oekelen, Oliver
    Parekh, Samir
    Cho, Hearn J.
    Vishnuvardhan, Nivetha
    Madduri, Deepu
    Richter, Joshua
    Ip, Chun
    Lau, Kenneth
    Florendo, Erika
    Mancia, Ines S.
    Thomas, Joanne
    Verina, Daniel
    Chan, Elaine
    Zarychta, Katarzyna
    La, Lisa
    Strumolo, Gina
    Melnekoff, David T.
    Leshchenko, Violetta V.
    Kim-Schulze, Seunghee
    Couto, Suzana
    Wang, Maria
    Pierceall, William E.
    Thakurta, Anjan
    Lagana, Alessandro
    Jagannath, Sundar
    Chari, Ajai
    LEUKEMIA & LYMPHOMA, 2020, 61 (09) : 2208 - 2215
  • [48] CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
    Lonial, Sagar
    Richardson, Paul
    Reece, Donna
    Mohamed, Hesham
    Shelat, Suresh
    San Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S330 - S330
  • [49] CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma.
    Lonial, Sagar
    Richardson, Paul G.
    Reece, Donna Ellen
    Mohamed, Hesham
    Shelat, Suresh
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Dedalo: Phase II Study of Daratumumab Plus Pomalidomide and Dexamethasone (DPd) in Patients with Relapsed/ Refractory Multiple Myeloma and 17p Deletion
    Montefusco, Vittorio
    Cafro, Anna Maria
    Casaluci, Gloria Margiotta
    Patriarca, Francesca
    Mina, Roberto
    D'Agostino, Mattia
    Capra, Andrea
    Priola, Claudia
    Dalla Palma, Anna Benedetta
    Rizzi, Rita
    Genua, Angelo
    Petrucci, Maria Teresa
    Paris, Laura
    Belotti, Angelo
    Cavo, Michele
    Conticello, Concetta
    Carlo-Stella, Carmelo
    Boccadoro, Mario
    BLOOD, 2022, 140 : 10193 - 10195
12345